Importantly, the signature was validated by applying public pan cancer EMT signatures to our data (reidentifying the PRRX1high subgroup), by applying the PRRX1 signature to three independent CLM datasets, and by protein expression analysis, supporting the reproducibility and relevance of the signature. Here, PRRX1 is linked to cancer.